M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
Early prophylaxis for VTE in patients with traumatic brain injury appears to be safe, although the decision of when to start should still depend on as...
Stopping a tumor necrosis factor inhibitor for nonmedical reasons such as increased copays, change of insurance, or loss of job health insurance is as...
Resveratrol increased cerebral blood vessel dilation in a small study of adults with type 2 diabetes mellitus, suggesting a possible role for slowing ...